Intranasal Anti-rabies DNA Immunization Promotes a Th1-related Cytokine Stimulation Associated with Plasmid Survival Time

Archives of Medical Research

Volumn 42, Issue 7, 2011, Pages 563-571

  Feria Romero, Iris Angélica ^a   Chávez Rueda, Karina ^b   Orozco Suárez, Sandra ^a   Blanco Favela, Francisco ^b   Calzada Bermejo, Fernando ^c   Chávez Sánchez, Luis ^b   Manuel Apolinar, Leticia ^b   Hernández González, Rafael ^d   Aguilar Setién, Álvaro ^b   Tesoro Cruz, Emiliano ^b,d  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c HOSPITAL DE PEDIATRÍA   (Mexico)

^d Nacional de Ciencias Médicas y Nutrición Salvador Zubirán   (Mexico)

Author keywords

Central nervous system; DNA vaccine; Intranasal; PGQH; Rabies; Th1 immune response

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; RABIES VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; PLASMID; PROTEIN EXPRESSION; RABIES; RNA TRANSCRIPTION; SURVIVAL TIME; TH1 TH2 BALANCE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; CYTOKINES; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION; RABIES VACCINES; TH1 CELLS; VACCINES, DNA;

EID: 84855484722     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.10.009     Document Type: Article

References (25)

1. Baer G., Bellini J.W., Fishbein D.B. Fields Virology 1990, Raven Press, New York, pp. 883-919. 2nd ed.
2. Weekly Epidemiological Record (WER) 7 December 2007, 82(49/50):425-436. World Health Organization.
3. Willoughby R.E., Tieves K.S., Hoffman G.M., et al. Survival after treatment of rabies with induction of coma. N Engl J Med 2005, 352:2508-2514.
4. Jackson A.C. Update on rabies diagnosis and treatment. Curr Infect Dis Rep 2009, 11:296-301.
5. Donelly J.J., Ulmer J.B., Shiver J.W., et al. DNA vaccines. Annu Rev Immunol 1997, 5:617-648.
6. Kowalczyk D., Ertl H. Immune responses to DNA vaccines. Cell Mol Life Sci 1999, 55:751-770.
7. Carvalho J.A., Prazeres D.M., Monteiro G.A. Bringing DNA vaccines closer to commercial use. Drugs 2009, 12:642-647.
8. Ertl H.C., Lanzavecchia A. Vaccines. Introduction. Curr Opin Immunol 2010, 22:355-357.
9. Bahloul Ch, Jacob Y., Tordo N., et al. DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses. Vaccine 1998, 16:417-425.
10. Perrin P., Jacob Y., Aguilar-Setién A., et al. Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine 1999, 18:479-486.
11. Tesoro-Cruz E., Calderón Rodríguez R., Hernández González R., et al. Intradermal into ear pinna (ID-EP) is an efficient route of immunization using a DNA anti-rabies vaccine in cats. Vet Res 2008, 39:16-24.
12. Tesoro-Cruz E., Feria-Romero I.A., López Mendoza J.G., et al. Efficient post-exposure prophylaxis against rabies by applying a four-dose DNA vaccine intranasally. Vaccine 2008, 26:6939-6944.
13. Fujihashi K., Koga T., McGhee J.R. Mucosal vaccination and immune responses in the elderly. Vaccine 2000, 18:1675-1680.
14. Lemiale F., Kong W.P., Akyurek L.M., et al. Enhanced mucosal immunoglobulin. A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. JVirol 2003, 77:10078-10087.
15. Tesoro Cruz E., Hernández González R., Alonso Morales R., et al. Rabies DNA vaccination by the intranasal route in dogs. Dev Biol 2006, 125:221-231.
16. Morimoto K., Shoji Y., Inoue S. Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity. Virus Res 2005, 111:61-67.
17. Ito N., Sugiyama M., Yamada K., et al. Characterization of M gene-deficient rabies virus with advantages of effective immunization and safety as a vaccine strain. Microbiol Immunol 2005, 49:971-979.
18. Cenna J., Tan G.S., Papaneri A.B., et al. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine 2008, 26:6405-6414.
19. Theofilopoulos A.N., Baccala R., Beutler B., et al. Type 1 interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-335.
20. Zhong W., Roberts A.D., Woodland D.L. Antibody-independent antiviral function if memory CD4+ T cells invivo requires regulatory signals from CD8+ effector T cells. J Immunol 2001, 167:1379-1386.
21. Iversen A.C., Norris P.S., Ware C.F., et al. Human NK cells inhibit cytomegalovirus replication through a noncytolytic mechanism involving lymphotoxin-dependent induction of IFN-β. J Immunol 2005, 175:7568-7574.
22. Saraya A., Wacharapluesadee S., Khawplod P., et al. A preliminary study of chemo- and cytokine responses in rabies vaccine recipients of intradermal and intramuscular regimens. Vaccine 2010, 28:4553-4557.
23. Talegaonkar S., Mishra P.R. Intranasal delivery: an approach to bypassthe blood brain barrier. Indian J Pharmacol 2004, 36:140-147.
24. Dufour V. DNA vaccines: new applications for veterinary medicine. Vet Sci Tomorrow 2001, 2:1-26.
25. Okada E., Sasaki S., Ishii N., et al. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997, 159:3638-3647.